AI Gains Ground in US Drug Fermentation

Early AI adoption in fermentation is giving U.S. drug makers sharper control, better yields, and more reliable scale-up

19 Dec 2025

Fermentation, a core step in the production of vaccines, biologics and advanced therapies, is beginning to attract attention from an unexpected source, artificial intelligence. Drug manufacturers across the US are testing AI tools to monitor and manage fermentation more closely, signalling a gradual shift in how medicines are made.

What started as limited pilot projects is moving into early deployment and scale-up. Companies are using AI systems to analyse streams of data from sensors tracking temperature, nutrients and oxygen, variables that can sharply affect living cells. By identifying patterns and early warning signs, the software aims to help operators respond faster to potential problems.

The push reflects wider pressures on the industry. Demand for biologic drugs continues to grow, while supply chains remain vulnerable and tolerance for production disruptions is shrinking. Fermentation processes are notoriously sensitive, and small deviations can lead to costly batch failures. AI offers clearer visibility into processes that often behave unpredictably.

Early results have been encouraging. In conference presentations and published case studies, companies report higher yields, fewer deviations and smoother transitions from development to commercial manufacturing. Analysts say the main benefit lies in consistency. AI tools can detect subtle trends that conventional monitoring may miss, allowing teams to intervene before problems escalate.

The move also fits with a broader shift towards digital manufacturing. US regulators, including the Food and Drug Administration, have encouraged data-driven approaches to quality and oversight without mandating AI-based control. This has given manufacturers scope to invest in digital platforms that strengthen documentation and decision-making while keeping humans responsible for final actions.

Contract development and manufacturing organisations are adopting similar tools. Many are partnering with software providers to add digital capabilities, reshaping competition in the sector. Data insight and process transparency are becoming as important as physical capacity and speed.

Challenges remain. Integrating data from older systems, protecting plants from cyber risks and building confidence in algorithm-assisted decisions all require investment and cultural change. Most industry observers, however, see these as manageable hurdles rather than structural barriers.

The next phase may involve digital twins that simulate fermentation runs before production begins. AI-driven fermentation is still at an early stage in the US, but its role in drug manufacturing is becoming harder to ignore.